Lafutidine-based triple therapy for Helicobacter pylori eradication
Abstract
BACKGROUND/AIMS: For treating Helicobacter pylori infection, it is still debatable whether proton pump inhibitor can be replaced by H2-receptor antagonist without compromising efficacy. Lafutidine is a newly synthesized H2-receptor antagonist and has been shown to exhibit antisecretory action. This meta-analysis investigated the efficacy of lafutidine-based triple therapy for Helicobacter pylori infection. METHODOGY: We searched PUBMED; EMBASE, the Cochrane Library and Chinese Biomedical Database databases to identify randomized controlled trials regarding lafutidine-based triple therapy of Helicobacter pylori eradication.
RESULTS: Thirteen potential studies were retrieved, of which 3 met our inclusion criteria. Overall we observed Helicobacter pylori eradication rates were similar in the lafutidine group and the lansoprazole group (OR, 1.03; 95% CI, 0.64-1.66). The OR for the active stage ulcer cure rate was 0.78 (95% CI, 0.35, 1.71) for lafutidine-based triple therapy compared with lansoprazole-based triple therapy. Likewise, we observed symptom response and adverse events were similar in both groups.
CONCLUSIONS: Lafutidine-based triple therapy was as safe and effective as triple therapy including lansoprazole for Helicobacter pylori infection, and could be considered as an additional treatment option. However, more rigorous research is required to accurately assess the role of lafutidine in eradicating Helicobacter pylori infection.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.